nitroglycerin

Our results demonstrated that Znhit1 ameliorated hyperalgesia and inhibited inflammatory response by suppressing the activation of NLRP3 inflammasome.

We also evaluated the effect of betamethasone on CGRP mRNA stability and release from the mouse TG, as well as on mouse spontaneous or nitroglycerin-induced cephalic allodynia.ResultsWe report that dexamethasone triggered transcriptional activation of the rat and human CGRP gene, also increasing transcript levels of RAMP1 but not of CLR in cultured cells. Of note, although a 13-fold increase of the CGRP releasable pool occurred in the TG of betamethasone-treated mice, the animals were not sensitized to cephalic allodynia.ConclusionsIn keeping with the emerging immunosuppressing effects of CGRP, corticosteroids increase its expression in rat and human cell lines, as well as in rodent TG. Evidence that a substantial increase of releasable CGRP in the TG does not reduce orofacial pain thresholds suggests that basal release of endogenous CGRP differs from its exogenous administration in terms of trigeminal afferent sensitization.

P=N/A, N=818, Not yet recruiting, Beijing Luhe Hospital, Capital Medical University; Beijing Luhe Hospital, Capital Medical University

On day 8, rat migraine models were established by subcutaneous injection of nitroglycerin...Warm needle acupuncture reduced ET-1 protein levels and promoted the expression of neurotransmitters, such as 5-hydroxytryptamine, in migraine rat model animals. In addition, needle warming acupuncture decreased IL-6, TNF-α, and CGRP levels in the brain stem of the migraine group, which may explain its mechanism of action in treating migraine.

P=N/A, N=20, Completed, Mansoura University

P=N/A, N=100, Not yet recruiting, Qilu Hospital of Shandong University

P1, N=15, Not yet recruiting, Johns Hopkins University | Initiation date: Aug 2025 --> Dec 2025 | Trial primary completion date: Jul 2026 --> Dec 2026

P1/2, N=60, Completed, Perth Children's Hospital(Child And Adolescent Health Service) | Recruiting --> Completed

In randomized stroke trials, the indirect NO donor glyceryl trinitrate lowered MAP but improved neither regional cerebral blood flow (rCBF) nor functional outcomes...During reperfusion, SIN-1 lowered MAP (P<0.001), decreased the no-reflow area (P=0.002), increased rCBF (P<0.001), increased spontaneous brain activity (P<0.001), and decreased extracellular potassium (P=0.008) and direct current potential (P=0.022) in both strains, consistent with less no-reflow and better recovery in SIN-1-treated animals. SIN-1 emerges as a promising antihypertensive in acute stroke as it paradoxically increases rCBF in ischemic tissue and reduces no-reflow.

P1, N=12, Active, not recruiting, Vanderbilt University | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Jul 2025 --> Jul 2026

P=N/A, N=4, Terminated, Montefiore Medical Center | N=10 --> 4 | Trial completion date: Jun 2026 --> Apr 2025 | Recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Apr 2025

This case highlights the challenge of 5-FU rechallenge in patients unable to take oral prophylaxis. Transdermal nitroglycerin monotherapy proved insufficient, suggesting that intravenous prophylaxis may be required. Future studies should determine optimal strategies for preventing CV in patients with a similar presentation.